A phase III trial, CAURAL, evaluated 29 patients with EGFRT790M-positive NSCLC to treat osimertinib (an EGFR inhibitor) plus durvalumab versus osimertinib monotherapy [72]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.